Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 15, Issue 6, 2016, Pages 809-815

  Flume, Patrick A ^a   Clancy, John P ^b   Retsch Bogart, George Z ^c   Tullis, D Elizabeth ^d   Bresnik, Mark ^e   Derchak, P Alex ^e   Lewis, Sandra A ^f   Ramsey, Bonnie W ^g  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e GILEAD SCIENCES   (United States)

^f Gilead Sciences   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aerosol; Antibiotics; Cystic fibrosis; Pseudomonas; Pulmonary exacerbation

Indexed keywords

AZTREONAM LYSINE; BRONCHODILATING AGENT; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT; AZTREONAM;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL EVALUATION; CONTINUOUS ALTERNATING THERAPY; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; MULTIPLE CYCLE TREATMENT; NEBULIZER KIT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RISK REDUCTION; TREATMENT OUTCOME; YOUNG ADULT; CLINICAL TRIAL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MEDICATION THERAPY MANAGEMENT; MULTICENTER STUDY; PSEUDOMONAS AERUGINOSA; TIME FACTOR;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; CHRONIC DISEASE; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84971622139     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.05.001     Document Type: Article

References (19)

1. [1] Mogayzel, P.J. Jr., Naureckas, E.T., Robinson, K.A., Mueller, G., Hadjiliadis, D., Hoag, J.B., et al. Pulmonary clinical practice guidelines. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187 (2013), 680–689.
2. [2] Smyth, A.R., Bell, S.C., Bojcin, S., Bryon, M., Duff, A., Flume, P., et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 13:Suppl. 1 (2014), S23–S42.
3. [3] Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340 (1999), 23–30.
4. [4] Konstan, M.W., Flume, P.A., Kappler, M., Chiron, R., Higgins, M., Brockhaus, F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 10 (2011), 54–61.
5. [5] Assael, B.M., Pressler, T., Bilton, D., Fayon, M., Fischer, R., Chiron, R., et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 12 (2013), 130–140.
6. [6] Oermann, C.M., Retsch-Bogart, G.Z., Quittner, A.L., Gibson, R.L., McCoy, K.S., Montgomery, A.B., et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 45 (2010), 1121–1134.
7. [7] Dasenbrook, E.C., Konstan, M.W., VanDevanter, D.R., Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 14 (2015), 370–375.
8. [8] Gilead Sciences Inc, Cayston® (aztreonam for inhalation solution) prescribing information., 2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050814s007lbl.pdf.
9. [9] Novartis Pharmaceuticals Corporation, TOBI® (tobramycin inhalation solution, USP) nebulizer solution. US prescribing information., 2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050753s016lbl.pdf.
10. [10] Hankinson, J.L., Odencrantz, J.R., Fedan, K.B., Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999), 179–187.
11. [11] Wang, X., Dockery, D.W., Wypij, D., Fay, M.E., Ferris, B.G. Jr., Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 15 (1993), 75–88.
12. [12] Quittner, A.L., Sawicki, G.S., McMullen, A., Rasouliyan, L., Pasta, D.J., Yegin, A., et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual. Life Res. 21 (2012), 1267–1278.
13. [13] University of Washington Departments of Medicine and Health Services, Cystic fibrosis respiratory symptom diary (CFRSD) — U.S. version 2.0 user manual. (Available from:) http://depts.washington.edu/seaqol/docs/CFRSD-CRISS_User_Manual.pdf.
14. [14] Dmitrienko, A., Offen, W.W., Westfall, P.H., Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 22 (2003), 2387–2400.
15. [15] Smith, A.L., Ramsey, B.W., Hedges, D.L., Hack, B., Williams-Warren, J., Weber, A., et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 7 (1989), 265–271.
16. [16] Moss, R.B., Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121 (2002), 55–63.
17. [17] McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z., Montgomery, A.B., Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 178 (2008), 921–928.
18. [18] Vandevanter, D.R., Yegin, A., Morgan, W.J., Millar, S.J., Pasta, D.J., Konstan, M.W., Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros 10 (2011), 453–459.
19. [19] VanDevanter, D.R., Pasta, D.J., Konstan, M.W., Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros, 2015.